Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 4/2014

01-04-2014 | Research Article

Change in expression of cyclin G2 in kidney cancer cell and its significance

Authors: D. W. Cui, G. G. Sun, Y. J. Cheng

Published in: Tumor Biology | Issue 4/2014

Login to get access

Abstract

This study aims to analyze the expression and clinical significance of cyclin G2 (CCNG2) in kidney carcinoma, and the biological effect in its cell line by CCNG2 overexpression. Immunohistochemistry and western blot were used to analyze CCNG2 protein expression in 63 cases of kidney cancer and normal tissues to study the relationship between CCNG2 expression and clinical factors. CCNG2 lentiviral vector and empty vector were respectively transfected into kidney ACHN cell line. During immunohistochemistry, the level of CCNG2 protein expression was found to be significantly lower in kidney cancer tissue than normal tissues (P < 0.05). After Western blot, the relative amount of CCNG2 protein in kidney cancer tissue was respectively found to be significantly lower than in normal tissues (P < 0.05). The level of CCNG2 protein expression was not correlated with gender, age, tumor size, and pathological types (P > 0.05), but it was correlated with lymph node metastasis, clinic stage, and histological grade (P < 0.05). Loss of CCNG2 expression correlated significantly with poor overall survival time by Kaplan–Meier analysis (P < 0.05). The result of biological function show that ACHN cell-transfected CCNG2 had a lower survival fraction, higher percentage of the G0/G1 phases, and lower CDK2 protein expression compared with ACHN cell-untransfected CCNG2 (P < 0.05). CCNG2 expression decreased in kidney cancer and correlated significantly with lymph node metastasis, clinical stage, histological grade, and poor overall survival, suggesting that CCNG2 may play important roles as a negative regulator to kidney cancer ACHN cell by promoting degradation of CDK2.
Literature
1.
Ljungberg B, Campbell SC, Cho HY, Jacqmin D, Lee JE, Weikert S, et al. The epidemiology of renal cell carcinoma. Eur Urol. 2011;60:615–21.PubMedCrossRef
2.
Tan X, He S, Han Y, Yu Y, Xiao J, Xu D, et al. Establishment and characterization of clear cell renal cell carcinoma cell lines with different metastatic potential from Chinese patients. Cancer Cell Int. 2013;13:20.PubMedCentralPubMedCrossRef
3.
Ahmed S, Al-Saigh S, Matthews J. FOXA1 is essential for aryl hydrocarbon receptor-dependent regulation of cyclin G2. Mol Cancer Res. 2012;10:636–48.PubMedCrossRef
4.
Bates S, Rowan S, Vousden KH. Characterization of human cyclin G1 and G2: DNA damage inducible genes. Oncogene. 1996;13:1103–9.PubMed
5.
Horne MC, Goolsby GL, Donaldson KL, Tran D, Neubauer M, Wahl AF. Cyclin G1 and cyclinG2 comprise a new family of cyclins with contrasting cycle-regulated expression. J Biol Chem. 1996;271:6050–61.PubMedCrossRef
6.
Kim Y, Shintani S, Kohno Y, Zhang R, Wong DT. Cyclin G2 dysregulation in human oral cancer. Cancer Res. 2004;64:8980–6.PubMedCrossRef
7.
Cui XF, Liu AJ, Xu ZM. Expression of cyclin G2 and its clinical significance in laryngeal squamous cell carcinoma. J Clin Otorhinolaryngol. 2009;23:277–9.
8.
Shan G, Shan SG, Zhang XB. Expression and clinical significance of cyclin G1 and cyclin G2 in transitional cell carcinoma of bladder. Chin J Histochem Cytochem. 2009;18:268–72.
9.
Choi MG, Noh JH, An JY, Hong SK, Park SB, Baik YH, et al. Expression levels of cyclin G2, but not cyclin E, correlate with gastric progression. J Surg Res. 2009;157:168–74.PubMedCrossRef
10.
Shi W, Yu KR, Wu GY, Zhang H. Expression of CCNG2 in gastric carcinorna and its relationship with prognosis. Chin J Cell Boil. 2011;33:994–7.
11.
Song YL, Hu GH. CyclinG2: correlation with head and neck neoplasms. Int J Otolaryngol-Head Neck Surg. 2006;30:8–11.
12.
Le XF, Arachehige-Don AS, Mao W, Horne MC, Bast Jr RC. Roles of human epidermal growth factor receptor 2, c-jun NH2-terminal kinase, phosphoinositide 3-kinase, and p70 S6 kinase pathways in regulation of cyclin G2 expression in human breast cancer cells. Mol Cancer Ther. 2007;6(11):2843–57.PubMedCrossRef
13.
Martinez-Gac L, Marqués M, García Z, Campanero MR, Carrera AC. Control of cyclinG2 mRNA expression by forkhead transcription factors: novel mechanism for cell cycle control by phosphoinositide 3-kinase and forkhead. Mol Cell Biol. 2004;4:2181–9.CrossRef
14.
Chen J, Yusuf L, Andersen HM, Fruman DA. FOXO transcription factors cooperate with delta EF1 to activate growth suppressive genes in B lymphocytes. J Immunol. 2006;76:2711–21.
15.
Xu G, Bernaudo S, Fu G, Lee DY, Yang BB, Peng C. CyclinG2 is degraded through the ubiquitin-proteasome pathway and mediates the antiproliferative effect of activin receptor-like kinase 7. Mol Biol Cell. 2008;9:4968–79.CrossRef
16.
Cellai C, Laurenzana A, Bianchi E, Sdelci S, Manfredini R, Vannucchi AM, et al. Mechanistic insight into WEB-2170-induced apoptosis in human acute myelogenous leukemia cells: the crucial role of PTEN. Exp Hematol. 2009;37:1176–85.PubMedCrossRef
17.
van Duijn PW, Ziel-van der Made AC, van der Korput JA, Trapman J. PTEN-mediated Gl cell-cycle arrest in LNCaP prostate cancer cells is associated with altered expression of cell-cycle regulators. Prostate. 2010;70:135–46.PubMed
18.
Horne MC, Donaldson KL, Goolsby GL, Tran D, Mulheisen M, Hell JW, et al. Cyclin G2 is up-regulated during growth inhibition and B cell antigen receptor-mediated cell cycle arrest. J Biol Chem. 1997;272:12650–61.PubMedCrossRef
19.
Bennin DA, Don AS, Brake T, McKenzie JL, Rosenbaum H, Ortiz L, et al. Cyclin G2 associates with protein phosphatase 2A catalytic and regulatory B′ subunits in active complexes and induces nuclear aberrations and a Gl/S phase cell cycle arrest. J Biol Chem. 2002;2779:27449–67.CrossRef
20.
Arachchige Don AS, Dallapiazza RF, Bennin DA, Brake T, Cowan CE, Horne MC. CyclinG2 is a centrosome-associated nucleocytoplasmic shuttling protein that influences microtubule stability and induces a P53-dependent cell cycle arrest. Exp Cell Res. 2006;312:4181–204.PubMedCentralPubMedCrossRef
Metadata
Title
Change in expression of cyclin G2 in kidney cancer cell and its significance
Authors
D. W. Cui
G. G. Sun
Y. J. Cheng
Publication date
01-04-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 4/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1415-6

Other articles of this Issue 4/2014

Tumor Biology 4/2014 Go to the issue

Research Article

Staphylococcal entorotoxin B anchored exosome induces apoptosis in negative esterogen receptor breast cancer cells

Research Article

BTG1 expression correlates with the pathogenesis and progression of breast carcinomas

Research Article

The association between polymorphism of P53 Codon72 Arg/Pro and hepatocellular carcinoma susceptibility: evidence from a meta-analysis of 15 studies with 3,704 cases

Research Article

MDM2 rs2279744 polymorphism and endometrial cancer: a meta-analysis

Research Article

Pyrosequencing analysis of BRCA1 methylation level in breast cancer cells

Research Article

Prediction of peritoneal recurrence by the mRNA level of CEA and MMP-7 in peritoneal lavage of gastric cancer patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits